000
| 02358cam 2200385zi 4500 |
---|
001 | 9.866265 |
---|
003 | CaOODSP |
---|
005 | 20221107162014 |
---|
006 | m o d f |
---|
007 | cr ||||||||||| |
---|
008 | 190530t20182018onca o f000 0 eng d |
---|
020 | |a9780660290669 |
---|
040 | |aCaOODSP|beng|erda|cCaOODSP |
---|
043 | |an-cn--- |
---|
086 | 1 |aH14-300/2019E-PDF |
---|
245 | 00|aVaping prevention concepts testing : |bfinal report / |cprepared by Corporate Research Associates Inc. for Health Canada. |
---|
264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |cSeptember 2018. |
---|
264 | 4|c©2018 |
---|
300 | |a1 online resource (1 volume (various pagings)) : |bcolour illustrations +|eexecutive summary (5 pages) |
---|
336 | |atext|btxt|2rdacontent |
---|
337 | |acomputer|bc|2rdamedia |
---|
338 | |aonline resource|bcr|2rdacarrier |
---|
500 | |aIssued also in French under title: Mise à l'essai de concepts sur la prévention du vapotage : rapport final. |
---|
500 | |aAccompanied by: executive summary. |
---|
504 | |aIncludes references. |
---|
520 | |a"Health Canada is in the process of developing the Health Risks of Vaping Products Public Awareness Marketing Campaign The campaign aims to increase awareness of the harms and risks associated with vaping product use by youth. Prior to campaign development, Health Canada was interested in assessing reactions from the campaign’s target audience to creative concepts being considered, including three concepts each including layouts for signage and social media posts (Phase one) and three storyboards/moodboards and three additional signage layouts (Phase two). Research was needed to ensure that the concepts resonated well with the target audience and addressed prevention in an effective manner"--Executive summary, page 1. |
---|
692 | 07|2gccst|aHealth hazards |
---|
692 | 07|2gccst|aMarketing campaigns |
---|
692 | 07|2gccst|aPublic opinion |
---|
693 | 4|aVaping |
---|
710 | 1 |aCanada. |bHealth Canada. |
---|
710 | 2 |aCorporate Research Associates. |
---|
775 | 08|tMise à l'essai de concepts sur la prévention du vapotage : |w(CaOODSP)9.866266 |
---|
856 | 40|qPDF|s6.09 MB|uhttps://publications.gc.ca/collections/collection_2019/sc-hc/H14-300-2019-eng.pdf|zReport |
---|
856 | 40|qPDF|s541 KB|uhttps://publications.gc.ca/collections/collection_2019/sc-hc/H14-300-2019-1-eng.pdf|zExecutive summary |
---|